The relative amplification of the genes varied substantially across the cancer types, with SETDB1 amplified in 20% of lung adenocarcinomas, NSD3 amplified in 21% of lung squamous cancers, and BRD4 amplified in 17% of ovarian serious adenocarcinomas (Figure 7C). Here, NSD3 is linked to cancer.